Evidence map›Paper›PMID 31358390›Full record

Trial reportOphthalmology2019

The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20.

Tiarnan D Keenan, Henry E Wiley, Elvira Agrón, Mary E Aronow, William G Christen, Traci E Clemons, Emily Y Chew, Age-Related Eye Disease Study and Age-Related Eye Disease Study 2 Research Groups

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Tiarnan D KeenanDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Henry E WileyDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Elvira AgrónDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Mary E AronowDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
William G ChristenDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Traci E ClemonsThe Emmes Corporation, Rockville, Maryland.
Emily Y ChewDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: echew@nei.nih.gov.
Age-Related Eye Disease Study and Age-Related Eye Disease Study 2 Research Groups
National Eye Institute · USBrigham and Women's Hospital · USEmmes (United States) · USNational Institutes of Health · US

Funding

THE LUTEIN/ZEAXANTHIN AND OMEGA-3 SUPPLEMENT TRIAL--A MULTI CENTER, RANDOMIZED TN01EY50007 · NEI · THE EMMES COMPANY, LLC · PI CLEMONS, TRACI · 2007 to 2011
$23.3M
The Age-Related Eye Disease Study 2 (AREDS2)ZIAEY000485 · NEI · NATIONAL EYE INSTITUTE · PI CHEW, EMILY Y · 2009 to 2015
$990k
Intramural NIH HHS ZIA EY000485NEI NIH HHS N01EY50007
6 · The paper itself

Abstract

purposeTo analyze the potential association between aspirin use and progression of age-related macular degeneration (AMD).

designTwo prospective cohort studies within 2 controlled clinical trials of oral supplementation for age-related eye disease.

participantsAge-Related Eye Disease Study (AREDS) participants 55 to 80 years of age and AREDS2 participants 50 to 85 years of age.

methodsPropensity scores for aspirin use were calculated for AREDS and AREDS2 participants separately by logistic regression. Of the participants without late AMD (geographic atrophy [GA] or neovascular AMD) in either eye at study baseline, aspirin users were matched 1:1 with nonusers by propensity score (separately for AREDS and AREDS2). Proportional hazards regression was performed, adjusting for age, on the matched participants to evaluate associations between aspirin propensity score and progression to late AMD (and its subtypes).

main outcome measuresProgression to late AMD on color fundus photographs, graded centrally.

resultsOf the 3734 eligible AREDS participants, 1049 (28.1%) were taking aspirin, and of the 2403 eligible AREDS2 participants, 1198 (49.9%) were taking aspirin. After matching by propensity score, the characteristics of the users and nonusers were similar in both studies. Of the 1950 matched AREDS participants and 1694 matched AREDS2 participants, over a median follow-up of 10.1 years and 5.0 years, respectively, the numbers who progressed to late AMD, GA, or neovascular AMD were 454 (23.3%), 345 (17.7%), and 278 (14.3%), respectively, in AREDS and 643 (38.0%), 402 (24.6%), and 341 (20.1%) in AREDS2. The hazard ratios of progression in quintile 5 (highest propensity for aspirin use) versus 1 (reference) were 1.17 (P = 0.35), 1.24 (0.25), and 0.95 (0.81), respectively, in AREDS and 1.26 (0.09), 1.46 (0.03), and 1.12 (0.58) in AREDS2. No significant association with progression to late AMD was observed for quintiles 2 through 5 for any of the 3 outcomes in either study.

conclusionsAspirin use was not associated significantly with progression to late AMD or its subtypes in either the AREDS or AREDS2. Patients with AMD need not avoid aspirin for this reason when its use is medically indicated.

Indexed as

Administration, OralAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAspirinDisease ProgressionFemaleFollow-Up StudiesGeographic AtrophyHumansMaleMiddle AgedNo-Observed-Adverse-Effect LevelProportional Hazards ModelsProspective StudiesWet Macular DegenerationAnti-Inflammatory Agents, Non-SteroidalAspirin

Identifiers

PMID31358390
PMCPMC6875604
OpenAlexW2954939062

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.